Acceptance of cpp-1x (dfmo) abstract for poster presentation at immunology of diabetes society meeting

Minneapolis, april 10, 2023 (globe newswire) -- panbela therapeutics, inc. (nasdaq: pbla), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs today announced that an abstract about cpp-1x (also known as dfmo or eflornithine) research, has been accepted for poster presentation at the immunology of diabetes society (ids) meeting, which will be held may 23-27, 2023.
PBLA Ratings Summary
PBLA Quant Ranking